Prognostic importance of COX-2 expression in patients with colorectal cancer

Yamaç, Deniz; Celenkoglu, Gokhan; Coşkun, Uğur; Akyürek, Nalân; Akçalı, Zafer; Dursun, Ayşe; Köybaşıoğlu, Fulya

doi:10.1016/j.prp.2005.04.006

Cited by 27 publications

(31 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are in agreement with those reported by other authors, 22,[43][44][45][46] who speculate that COX-2 might exert a crucial role in early carcinogenesis and in the acquisition of a neoplastic phenotype by PGE 2 -mediated induction of the Bcl2 protoncogene. 47 However, according to these authors, invasiveness and metastatic potential would require not only COX-2 mediated angiogenesis 4,17 but also other genes and proteins, such as MT1-MMP and MMP-2.…”

Section: Discussionsupporting

confidence: 94%

5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

Barresi¹,

Grosso²,

Vitarelli³

et al. 2007

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 94%

5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

Barresi¹,

Grosso²,

Vitarelli³

et al. 2007

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

show abstract

“…Some previous studies demonstrated similar results, 23,24 although others considered COX-2 overexpression an independent prognostic factor associated with reduced DFS in patients with CRC. 48,49 In conclusion, our data revealed a high frequency of p53 mutations with multiple mutations in the same patient and a unique mutational hotspot at codon 4, which nay be attributed to different environmental and etiologic effects, such as chronic inflammatory conditions, rather than dietary habits or racial differences. The data also provide evidence that c-Kit, p53 codon 72, and K-ras codon 12 are independent prognostic factors in patients with stage II CRC and should be considered in predicting the clinical outcome of patients and in individualizing their therapy.…”

Section: Discussionmentioning

confidence: 64%

The prognostic value of c‐Kit, K‐ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer

El-Serafi

Bahnassy

Ali

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The prognosis for patients with colorectal cancer (CRC) depends mainly on standard clinicopathologic factors. However, patients with similar disease characteristics exhibit various outcomes, especially in stage II. Therefore, the identification of molecular prognostic markers is needed to predict patient outcomes. METHODS: The authors assessed the prognostic value of c-Kit (also called cluster of differentiation 117 [CD117] or KIT), cyclooxygenase-2 (COX-2), tumor protein 53 (p53), and Kirsten rat sarcoma viral oncogene homolog (K-ras) aberrations in 90 patients with stage II CRC using immunohistochemistry and molecular techniques. The results were correlated with standard clinicopathologic prognostic factors, overall survival (OS), and disease-free survival (DFS). RESULTS: COX2 and c-Kit overexpression was detected in 54.6% and 59.3% of patients, respectively. Overexpression of p53 was detected in 47 patients, including 29 who had mutations, and a unique mutation pattern was detected with 3 hotspots at codons 72, 245, and 273. Overexpression of ras was detected in 44 patients, including 37 who had mutations. On multivariate analysis, c-Kit overexpression, p53 codon 72 mutations, perforation, and performance status were independent prognostic factors for DFS (P ¼ .054, P ¼ .015, P < .0001, and P ¼ .043, respectively); whereas codon 12 K-ras mutation, performance status, and perforation were independent prognostic factors for OS (P ¼ .033, P ¼ .006, and P < .0001, respectively). CONCLUSIONS: The current results provide evidence for the prognostic value of c-Kit overexpression in patients with stage II CRC. The high p53 mutation rate and the unique hotspot in codon 72 have not been reported previously in CRC. This may be related to environmental or racial features that are unique to the studied population. Cancer 2010;116:4954-64.

show abstract

“…In addition, intratumoral expression of COX-2 has been independently associated with tumor differentiation,17 angiogenesis,48,49 recurrence,50 and metastasis 51. Moreover, COX-2 expression has been correlated with worsened patient survival in some13-16,48 but not all studies 17,18,52,53…”

Section: Commentmentioning

confidence: 99%

Aspirin Use and Survival After Diagnosis of Colorectal Cancer

Chan

Ogino²,

Fuchs³

2009

JAMA

500

407

View full text Add to dashboard Cite

Context Aspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models. However, the influence of aspirin on survival after diagnosis of colorectal cancer is unknown.Objective To examine the association between aspirin use after colorectal cancer diagnosis on colorectal cancer−specific and overall survival. Design, Setting, and Participants Prospective cohort study of 1279 men and women diagnosed with stage I, II, or III colorectal cancer. Participants were enrolled in 2 nationwide health professional cohorts in 1980 and 1986 prior to diagnosis and followed up through June 1, 2008. Main Outcome Measure Colorectal cancer−specific and overall mortality.Results After a median follow-up of 11.8 years, there were 193 total deaths (35%) and 81 colorectal cancer−specific deaths (15%) among 549 participants who regularly used aspirin after colorectal cancer diagnosis, compared with 287 total deaths (39%) and 141 colorectal cancer−specific deaths (19%) among 730 participants who did not use aspirin. Compared with nonusers, participants who regularly used aspirin after diagnosis experienced a multivariate hazard ratio (HR) for colorectal cancer−specific mortality of 0.71 (95% confidence interval [CI], 0.53-0.95) and for overall mortality of 0.79 (95% CI, 0.65-0.97). Among 719 participants who did not use aspirin before diagnosis, aspirin use initiated after diagnosis was associated with a multivariate HR for colorectal cancer−specific mortality of 0.53 (95% CI, 0.33-0.86). Among 459 participants with colorectal cancers that were accessible for immunohistochemical assessment, the effect of aspirin differed significantly according to cyclooxygenase 2 (COX-2) expression (P for interaction = .04). Regular aspirin use after diagnosis was associated with a lower risk of colorectal cancer−specific mortality among participants in whom primary tumors overexpressed COX-2 (multivariate HR, 0.39; 95% CI, 0.20-0.76), whereas aspirin use was not associated with lower risk among those with primary tumors with weak or absent expression (multivariate HR, 1.22; 95% CI, 0.36-4.18). ConclusionRegular aspirin use after the diagnosis of colorectal cancer is associated with lower risk of colorectal cancer−specific and overall mortality, especially among individuals with tumors that overexpress COX-2.

show abstract

Prognostic importance of COX-2 expression in patients with colorectal cancer

Cited by 27 publications

References 23 publications

5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

The prognostic value of c‐Kit, K‐ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer

Aspirin Use and Survival After Diagnosis of Colorectal Cancer

Contact Info

Product

Resources

About